Niels Emmerich CEO at BioPheresis

BioPheresis GmbH, a biomedical technology company focused on tumour immunotherapy, has appointed Dr. Niels Emmerich as Chief Executive Officer. Joining from Immatics Biotechnologies, where he was Chief Operating officer and also a Co-Founder, Neils has also been a strategic management consultant at McKinsey & Company. He holds a PhD in Immunology and a MSc in Biology, both from the University of Tuebingen, where he was also a member of the research staff in the Department of Immunology.

“It is long since known that tumour cells and tissue actively release certain proteins into the blood in order to inhibit the immune system and to protect the tumor from being destroyed. BioPheresis and its investors recognised the potential of the scientific concept to remove these inhibitors from the blood of tumor patients and developed the OncoSorb therapy,” commented Niels Emmerich, CEO of BioPheresis.
“I am excited to work with the company to take this proprietary technology to the next level. BioPheresis is well positioned to set the pace in the field of therapeutic apheresis for cancer treatment, and I am impressed by the team and by the growth potential of the company.”

Hugh Stevenson, Chairman of the Board of BioPheresis, added: “With the start of a second clinical trial of the OncoSorb technology, BioPheresis has reached an important milestone. At this stage, Niels Emmerich is the ideal candidate for fostering the future growth of the company. His experience and skills will help BioPheresis to successfully reach the next stage in corporate and product development.”